Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Xofluza to Join NHI Price List March 14 as Key Panel Gives Expedited OK
March 7, 2018
- 10 Billion Yen Could Be Saved If 80% Gx Use Achieved among Welfare Recipients: Govt
March 6, 2018
- New Authorized Generic Re-Pricing Rule Applied to Olmetec, Crestor AGs
March 6, 2018
- Rituxan Biosimilar Price Down 9.5% as Originator Hit by Re-Pricing
March 6, 2018
- Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
- Annual Savings from Use of Biosimilars Stands at Just 8.7 Billion Yen: MHLW
March 6, 2018
- Hemophilia A Treatment Hemlibra, Zoster Vaccine Shingrix Clear MHLW Panel
March 5, 2018
- One-Time Blockbusters to Be Re-Priced at 2.5-Times Gx Price Average; Mevalotin, Takepron among the List
March 5, 2018
- Repatha Gets Price Raise as It Wins Post-Launch Premium for CV Risk Reduction
March 5, 2018
- 314 APIs Eligible for Price Maintenance Premium in FY2018, Down from 416
March 5, 2018
- Opdivo Faces 23.8% Price Cut as Slew of Reduction Rules Apply; Nexium Down 16.1% on Huge Seller Slash
March 5, 2018
- MHLW Unveils New List Prices, Post-Launch Foreign Price Adjustment Applied Only to Opdivo
March 5, 2018
- MHLW Panel Backs Nobelpharma’s Sirolimus Gel, Azilect, Januvia-Suglat Combo and More
March 2, 2018
- Enforcement Regulations of Clinical Research Law Promulgated
March 2, 2018
- Junior LDP Lawmakers Question Drug Pricing: Fiscal Structure Panel
March 1, 2018
- MHLW Still Pondering Steps to Ensure Proper Sales Activities by Drug Reps
February 28, 2018
- MHLW Weighs Amendment to PMD Law as It Looks Beyond 2025: Bureau Chief
February 28, 2018
- Japan Approves 23 NMEs in 2017, Lowest in Past 5 Years
February 28, 2018
- PMDA to Take Applications for Using MID-NET Starting April 1
February 27, 2018
- Clinical Research Law to Take Effect on April 1
February 26, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…